Asunto(s)
Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Tiazidas/uso terapéutico , Monitoreo Ambulatorio de la Presión Arterial/métodos , Anhidrasas Carbónicas/efectos de los fármacos , Clortalidona/farmacocinética , Clortalidona/uso terapéutico , Diuréticos/uso terapéutico , Endotelio/efectos de los fármacos , Endotelio/metabolismo , Endotelio/fisiología , Guías como Asunto , Humanos , Hipertensión/fisiopatología , Agregación Plaquetaria/efectos de los fármacos , Estudios Retrospectivos , Inhibidores de los Simportadores del Cloruro de Sodio/farmacología , Inhibidores de los Simportadores del Cloruro de Sodio/uso terapéuticoRESUMEN
A novel, precise, sensitive and accurate ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method has been developed for the simultaneous determination of a novel drug combination, candesartan (CAN) and chlorthalidone (CHL), in human plasma. Chromatographic separation was achieved on Waters Acquity UPLC BEH C18 (50 × 2.1 mm, 1.7 µm). Mobile phase consisting of 1 mm ammonium acetate in water-acetonitrile (20:80 v/v) was used. The total chromatographic runtime was 1.9 min with retention times for CAN and CHL at 0.7 and 1.1 min respectively. Ionization and detection of analytes and internal standards was performed on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring and negative ionization mode. Quantitation was done to monitor protonated precursor â product ion transition of m/z 439.2 â 309.0 for CAN, 337.0 â 189.8 for CHL and 443.2 â 312.1 for candesartan D4 and 341.0 â 189.8 for chlorthalidone D4. The method was validated over a wide dynamic concentration range of 2.0-540.0 ng/mL for candesartan and 1.0-180.0 ng/mL for chlorthalidone. The validated method was successfully applied for the assay of CAN and CHL in healthy volunteers.
Asunto(s)
Bencimidazoles/sangre , Clortalidona/sangre , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Tetrazoles/sangre , Adolescente , Adulto , Bencimidazoles/química , Bencimidazoles/farmacocinética , Compuestos de Bifenilo , Clortalidona/química , Clortalidona/farmacocinética , Combinación de Medicamentos , Estabilidad de Medicamentos , Humanos , Límite de Detección , Modelos Lineales , Persona de Mediana Edad , Reproducibilidad de los Resultados , Tetrazoles/química , Tetrazoles/farmacocinética , Adulto JovenRESUMEN
A pharmacokinetic-pharmacodynamic (PK-PD) model was developed to describe the time course of blood pressure following oral administration of azilsartan medoxomil (AZM) and/or chlorthalidone (CLT) in spontaneously hypertensive (SH) rats. The drug concentration and pharmacological effects, including systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and tail-cuff manometry, respectively. Sequential PK-PD analysis was performed, wherein the plasma concentration-time data was modeled by one compartmental analysis. Subsequently PD parameters were calculated to describe the time-concentration-response relationship using indirect response (IDR) PK-PD model. The combination of AZ and CLT had greater BP lowering effect compared to AZ or CLT alone, despite of no pharmacokinetic interaction between two drugs. These findings suggest synergistic antihypertensive pharmacodynamic interaction between AZ and CLT noncompetitively, which was simulated by inhibitory function of AZ and stimulatory function of CLT after concomitant administration of the two drugs. The present model was able to capture the turnover of blood pressure adequately at different time points at two different dose levels. The current PK-PD model was successfully utilized in the simulation of PD effect at a dose combination of 0.5 and 2.5 mg/kg for AZ and CLT, respectively. The developed preclinical PK-PD model may provide guidance in the optimization of dose ratio of individual drugs in the combined pharmacotherapy of AZ and CLT at clinical situations.
Asunto(s)
Bloqueadores del Receptor Tipo 1 de Angiotensina II/farmacocinética , Antihipertensivos/farmacocinética , Bencimidazoles/farmacocinética , Presión Sanguínea/efectos de los fármacos , Clortalidona/farmacocinética , Hipertensión/tratamiento farmacológico , Modelos Biológicos , Oxadiazoles/farmacocinética , Inhibidores de los Simportadores del Cloruro de Sodio/farmacocinética , Administración Oral , Bloqueadores del Receptor Tipo 1 de Angiotensina II/administración & dosificación , Animales , Antihipertensivos/administración & dosificación , Bencimidazoles/administración & dosificación , Clortalidona/administración & dosificación , Cromatografía Liquida , Simulación por Computador , Modelos Animales de Enfermedad , Monitoreo de Drogas/métodos , Sinergismo Farmacológico , Quimioterapia Combinada , Hipertensión/diagnóstico , Hipertensión/fisiopatología , Oxadiazoles/administración & dosificación , Ratas Endogámicas SHR , Inhibidores de los Simportadores del Cloruro de Sodio/administración & dosificación , Espectrometría de Masas en TándemRESUMEN
Azilsartan medoxomil is a long-acting angiotensin II receptor blocker used to treat hypertension as monotherapy or in fixed-dose combination (FDC) with chlorthalidone. This study assessed the effects of food intake on the plasma pharmacokinetics of the active moiety, azilsartan, and of chlorthalidone when administered as separate tablets or in FDC. Cohort 1 (n = 24) received azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) once in a fasted condition and once 30 minutes after the initiation of a high-fat meal (fed). Cohort 2 (n = 24) received the same drugs as an FDC tablet in the fasted and fed conditions. In cohort 1, the fed-fasted ratios for AUC0-inf and Cmax were 108.3 (101.6-115.5) and 103.7 (94.3-114.1), respectively, for azilsartan and 112.3 (106.5-118.4) and 100.3 (90.6-111.1), respectively, for chlorthalidone. In cohort 2, the corresponding ratios were 78.6 (67.6-91.4) and 78.6 (64.4-96.0) for azilsartan and 101.0 (96.5-86.7) and 75.9 (66.5-86.7) for chlorthalidone. The combination therapies were well tolerated, and food intake had no consistent effect on adverse events. Food intake had a somewhat greater effect on plasma pharmacokinetics after administration of the FDC tablet than after administration of separate tablets, but the effects of food on the plasma pharmacokinetics of the FDC were not expected to be clinically meaningful.
Asunto(s)
Antihipertensivos/administración & dosificación , Bencimidazoles/administración & dosificación , Clortalidona/administración & dosificación , Interacciones Alimento-Droga , Oxadiazoles/administración & dosificación , Adulto , Bloqueadores del Receptor Tipo 1 de Angiotensina II/administración & dosificación , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Bloqueadores del Receptor Tipo 1 de Angiotensina II/farmacocinética , Antihipertensivos/efectos adversos , Antihipertensivos/farmacocinética , Bencimidazoles/efectos adversos , Bencimidazoles/farmacocinética , Clortalidona/efectos adversos , Clortalidona/farmacocinética , Estudios de Cohortes , Grasas de la Dieta/administración & dosificación , Combinación de Medicamentos , Ayuno , Femenino , Humanos , Masculino , Oxadiazoles/efectos adversos , Oxadiazoles/farmacocinética , Comprimidos , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVE: Combination therapy is recommended for the effective management of hypertension according to most treatment guidelines, including those of the US Joint National Committee. Therefore, pharmacokinetic drug interactions are an important issue in combination therapy for hypertension. In this study, the pharmacokinetic properties of telmisartan and chlorthalidone were evaluated to investigate their pharmacokinetic interactions in healthy subjects. METHODS: Two separate, randomized, multiple-dose, two-period, one-sequence studies were conducted. In study A, 43 participants received 80 mg of telmisartan orally for 7 days, and were then administered oral chlorthalidone 25 mg for 14 days (days 8-21), coadministered with 80 mg of telmisartan from day 15. In study B, 14 participants received oral chlorthalidone (25 mg) for 13 days, followed by coadministration with 80 mg of telmisartan orally for 7 days. RESULTS: The geometric mean ratios (GMRs) (90 % confidence intervals [CIs]) of the maximum plasma concentration (C max,ss) and area under the concentration-time curve for the dosing interval at steady state (AUCτ,ss) of telmisartan (with and without chlorthalidone) were 1.018 (0.861-1.203) and 1.099 (1.015-1.190), respectively. For chlorthalidone (with/without telmisartan), the GMRs (90 % CIs) for C max,ss and AUCτ,ss were 0.996 (0.922-1.075) and 0.992 (0.925-1.064), respectively. The GMRs and 90 % CIs for telmisartan and chlorthalidone were all within the 0.80-1.25 range. CONCLUSION: Thus, in this study, there was no significant pharmacokinetic interaction between telmisartan and chlorthalidone. CLINICALTRIAL. GOV IDENTIFIER: NCT01806363.
Asunto(s)
Bloqueadores del Receptor Tipo 1 de Angiotensina II/farmacocinética , Antihipertensivos/farmacocinética , Bencimidazoles/farmacocinética , Benzoatos/farmacocinética , Clortalidona/farmacocinética , Diuréticos/farmacocinética , Adulto , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Antihipertensivos/efectos adversos , Área Bajo la Curva , Bencimidazoles/efectos adversos , Benzoatos/efectos adversos , Clortalidona/efectos adversos , Diuréticos/efectos adversos , Interacciones Farmacológicas , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana Edad , Telmisartán , Adulto JovenRESUMEN
A simple, sensitive and reproducible ultra-performance liquid chromatography-tandem mass spectrometry method has been developed for the simultaneous determination of atenolol, a ß-adrenergic receptor-blocker and chlorthalidone, a monosulfonamyl diuretic in human plasma, using atenolol-d7 and chlorthalidone-d4 as the internal standards (ISs). Following solid-phase extraction on Phenomenex Strata-X cartridges using 100 µL human plasma sample, the analytes and ISs were separated on an Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 µm) column using a mobile phase consisting of 0.1% formic acid-acetonitrile (25:75, v/v). A tandem mass spectrometer equipped with electrospray ionization was used as a detector in the positive ionization mode for both analytes. The linear concentration range was established as 0.50-500 ng/mL for atenolol and 0.25-150 ng/mL for chlorthalidone. Extraction recoveries were within 95-103% and ion suppression/enhancement, expressed as IS-normalized matrix factors, ranged from 0.95 to 1.06 for both the analytes. Intra-batch and inter-batch precision (CV) and accuracy values were 2.37-5.91 and 96.1-103.2%, respectively. Stability of analytes in plasma was evaluated under different conditions, such as bench-top, freeze-thaw, dry and wet extract and long-term. The developed method was superior to the existing methods for the simultaneous determination of atenolol and chlorthalidone in human plasma with respect to the sensitivity, chromatographic analysis time and plasma volume for processing. Further, it was successfully applied to support a bioequivalence study of 50 mg atenolol + 12.5 mg chlorthalidone in 28 healthy Indian subjects.
Asunto(s)
Atenolol/sangre , Clortalidona/sangre , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Atenolol/química , Atenolol/farmacocinética , Clortalidona/química , Clortalidona/farmacocinética , Estabilidad de Medicamentos , Humanos , Modelos Lineales , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Population pharmacokinetic and exposure-response models for azilsartan medoxomil (AZL-M) and chlorthalidone (CLD) were developed using data from an 8-week placebo-controlled phase 3, factorial study of 20, 40, and 80 mg AZL-M every day (QD) and 12.5 and 25 mg CLD QD in fixed-dose combination (FDC) in subjects with moderate to severe essential hypertension. A 2-compartment model with first-order absorption and elimination was developed to describe pharmacokinetics. An Emax model for exposure-response analysis evaluated AZL-M/CLD effects on ambulatory systolic blood pressure (SBP). Estimated oral clearance and apparent volume of distribution (central compartment) were 1.47 L/h and 3.98 L for AZL, and 4.13 L/h and 62.1 L for CLD. Age as a covariate had the largest effect on AZL and CLD exposure (±20% change). Predicted maximal SBP responses (Emax ) were -15.6 and -23.9 mm Hg for AZL and CLD. Subgroup analysis identified statistically significant Emax differences for black vs nonblack subjects, whereby the reduced AZL response in black subjects was offset by greater response to CLD. The estimated Emax for AZL and CLD was generally greater in subjects with higher baseline BP. In conclusion, no dose adjustments to AZL-M or CLD are warranted based on identified covariates, and antihypertensive efficacy of AZL-M/CLD combination therapy is comparable in black and nonblack subjects.
Asunto(s)
Bencimidazoles/administración & dosificación , Bencimidazoles/sangre , Clortalidona/administración & dosificación , Clortalidona/sangre , Hipertensión/sangre , Hipertensión/tratamiento farmacológico , Oxadiazoles/administración & dosificación , Oxadiazoles/sangre , Anciano , Bloqueadores del Receptor Tipo 1 de Angiotensina II/administración & dosificación , Bloqueadores del Receptor Tipo 1 de Angiotensina II/sangre , Bloqueadores del Receptor Tipo 1 de Angiotensina II/farmacocinética , Antihipertensivos/administración & dosificación , Antihipertensivos/sangre , Antihipertensivos/farmacocinética , Bencimidazoles/farmacocinética , Clortalidona/farmacocinética , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oxadiazoles/farmacocinética , Resultado del TratamientoRESUMEN
Azilsartan medoxomil (AZM), an ester prodrug of azilsartan (AZ), and chlorthalidone (CLT) have recently been approved as a combination therapy for the management of hypertension. This is the first report which described a selective and sensitive method for the simultaneous quantification of AZ and CLT in rat and human plasma using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). AZ and CLT were extracted from plasma by liquid-liquid extraction technique and separated on a C18 reverse phase column using ammonium acetate (10mM, pH 4)-mixture of methanol and acetonitrile (8:92, v/v) as a mobile phase at a flow rate of 0.7mL/min. Detection was performed by electrospray ionization (ESI) operated in negative multiple reaction monitoring (MRM) mode. The lower limit of quantitation (LLOQ) of this method was 1ng/mL and the calibration curves were linear (r(2)≥0.995) over the concentration range of 1-4000ng/mL for both the analytes. The intra- and inter-day precision and accuracy were well within the acceptable limits. The mean extraction recoveries were found to be about 80% and no matrix effect was observed. AZ and CLT were found to be stable under all relevant storage conditions. The method was successfully applied to the oral pharmacokinetic study of AZM and CLT in rats. Further, the sensitivity of the method enabled the determination of protein binding of AZ and CLT in human plasma.
Asunto(s)
Bencimidazoles/sangre , Clortalidona/sangre , Cromatografía Liquida/métodos , Oxadiazoles/sangre , Espectrometría de Masas en Tándem/métodos , Animales , Bencimidazoles/química , Bencimidazoles/farmacocinética , Clortalidona/química , Clortalidona/farmacocinética , Humanos , Modelos Lineales , Masculino , Oxadiazoles/química , Oxadiazoles/farmacocinética , Unión Proteica , Ratas , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Chlorthalidone's safety and efficacy in the management of hypertension has been demonstrated in landmark trials. Despite understanding the effects of thiazides on urinary sodium excretion and intravascular volume, the exact mechanism of their antihypertensive effects is not clearly understood. Common compensatory mechanisms for decreases in circulating plasma volume include increased adrenergic tone and systemic vascular resistance, as well as increases in the renin-angiotensin-aldosterone system. Chlorthalidone has been shown to decrease platelet aggregation and vascular permeability and promote angiogenesis in vitro, which is thought to be, in part, the result of reductions in carbonic anhydrase-dependent pathways, including catecholamine-mediated platelet aggregation and downregulation of VEGF-C gene expression. This article reviews the comparative clinical data between chlorthalidone and hydrochlorothiazide, the pharmacologic properties that might explain some of their differences regarding half-life and efficacy, and what is known about the effect of chlorthalidone on intermediate endpoints.
Asunto(s)
Antihipertensivos/uso terapéutico , Clortalidona/uso terapéutico , Diuréticos/uso terapéutico , Hipertensión/tratamiento farmacológico , Antihipertensivos/farmacocinética , Antihipertensivos/farmacología , Clortalidona/farmacocinética , Clortalidona/farmacología , Diuréticos/farmacocinética , Diuréticos/farmacología , Humanos , Hidroclorotiazida/farmacología , Hidroclorotiazida/uso terapéuticoRESUMEN
Pharmacokinetic (PK) studies in mice usually require discrete and parallel blood sampling owing to a restriction on the volume of blood that can be withdrawn. This results in dosing large number of animals and generating composite PK profile. To reduce the number of animals and generate individual animal PK profiles, we developed a serial sampling technique via tail vein bleeding in mice, in which only 20-30 µL blood was withdrawn per time point. Due to the small blood volume, a dried-blood spot (DBS) technique was applied for sample processing. The utility of this technique was demonstrated using three test compounds (amodiaquine, chloroquine and chlorthalidone), with varying degrees of blood-to-plasma partition ratios. The PK studies were carried out in male Balb/c mouse weighing 25-30 g. The compounds were administered intravenously via the saphenous vein. Blood was collected by composite (retro-orbital plexus) or serial (tail vein bleeding) sampling techniques at different time points. Blood samples were processed as blood lysate or DBS. Blood or plasma samples were analyzed by sensitive and rapid UPLC-MS/MS methods. The blood concentrations (both from blood lysate and DBS) obtained from serial sampling matched with those from composite sampling. The ratio of blood AUC to plasma AUC correlated well with the in vitro blood-to-plasma partition ratio of the compounds. The systemic clearance and volume of distribution at steady state calculated from blood or plasma AUCs were in proportion to the respective AUCs. Our results indicated that the serial sampling technique would reduce the number of animals and also compound usage, as well as improve the quality of pharmacokinetic data. Also, the serial sampling technique does not require the use of anesthesia and allows estimation of inter-animal variability in PK. A small volume serial sampling is possible due to the availability of the DBS technique.
Asunto(s)
Recolección de Muestras de Sangre/métodos , Cromatografía Líquida de Alta Presión/métodos , Pruebas con Sangre Seca/métodos , Espectrometría de Masas en Tándem/métodos , Amodiaquina/farmacocinética , Animales , Área Bajo la Curva , Cloroquina/farmacocinética , Clortalidona/farmacocinética , Inyecciones Intravenosas , Masculino , Ratones , Ratones Endogámicos BALB C , Sensibilidad y Especificidad , Factores de Tiempo , Distribución TisularRESUMEN
A method based on a simple liquid-liquid extraction (LLE) followed by high-performance liquid chromatography with negative ion electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) detection was developed for the simultaneous determination of losartan (LOS) and hydrochlorothiazide (HCTZ) in human plasma, using valsartan (VAL) and chlorthalidone (CHTD) as an internal standard, respectively. The acquisition was performed in multiple reactions monitoring (MRM) and the limit of quantification was 4 ng/mL for both LOS and HCTZ. The method was linear in the studied range (4-800 ng/mL for LOS and 4-500 ng/mL for HCTZ). The intra-assay precisions ranged from 2.6-11.9% for LOS and 1.4-8.2% for HCTZ, while the inter-assay precisions ranged from 1.0-8.0% for LOS and 2.5-7.7% for HCTZ. The intra-assay accuracies ranged from 91.3 to 107.6% for LOS and 91.5 to 105.8% for HCTZ, while the inter-assay accuracies ranged from 99.9 to 106.4% for LOS and 97.4 to 101.4% for HCTZ. The analytical method was applied to a bioequivalence study, in which 28 healthy adult volunteers (14 men) received single oral doses (100 mg LOS + 25 mg HCTZ) of reference and test formulations, in an open, two-period, balanced randomized, crossover protocol. Based on the 90% confidence interval of the individual ratios for Cmax and AUC0-inf, it was concluded that the test formulation is bioequivalent to the reference Hyzaar formulation with respect to the rate and extent of absorption of both LOS and HCTZ.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Hidroclorotiazida/sangre , Hidroclorotiazida/farmacocinética , Losartán/sangre , Losartán/farmacocinética , Espectrometría de Masa por Ionización de Electrospray/métodos , Administración Oral , Adulto , Clortalidona/sangre , Clortalidona/farmacocinética , Estudios Cruzados , Femenino , Humanos , Hidroclorotiazida/administración & dosificación , Losartán/administración & dosificación , Masculino , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Tetrazoles/sangre , Tetrazoles/farmacocinética , Equivalencia Terapéutica , Valina/análogos & derivados , Valina/sangre , Valina/farmacocinética , ValsartánRESUMEN
Diuretic therapy remains a mainstay of hypertension treatment, either given as monotherapy or used in combination with other antihypertensive compounds. Several issues have complicated the issue of diuretic use with that of class effect being the one that has proven most difficult. Hydrochlorothiazide is a commonly used thiazide diuretic; whereas chlorthalidone is a structurally similar compound, quite dissimilar pharmacokinetically with a much longer half-life for effect and a wider volume of distribution with heavy partitioning in red blood cells. These pharmacokinetic features afford chlorthalidone a unique advantage in its capacity to act as an effective diuretic and blood-pressure-lowering agent, as well as a compound that improves cardiovascular outcomes in the patient with hypertension. Chlorthalidone has been used sparingly in clinical practice in large measure because it is not readily available in many fixed-dose combination products. Fixed-dose combinations containing chlorthalidone and an angiotensin-receptor blocker are now in development. It remains to be determined how well these two therapies will reduce blood pressure in the general population while keeping compound-specific side effects to a minimum.
Asunto(s)
Antihipertensivos/uso terapéutico , Clortalidona/uso terapéutico , Diuréticos/uso terapéutico , Hipertensión/tratamiento farmacológico , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Antihipertensivos/farmacocinética , Clortalidona/farmacocinética , Diuréticos/farmacocinética , Combinación de Medicamentos , Humanos , Hipertensión/metabolismo , Losartán/uso terapéuticoAsunto(s)
Clortalidona/uso terapéutico , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Inhibidores de los Simportadores del Cloruro de Sodio/uso terapéutico , Clortalidona/farmacocinética , Humanos , Hidroclorotiazida/farmacocinética , Pautas de la Práctica en Medicina , Ensayos Clínicos Controlados Aleatorios como Asunto , Inhibidores de los Simportadores del Cloruro de Sodio/farmacocinéticaAsunto(s)
Presión Sanguínea/efectos de los fármacos , Clortalidona/uso terapéutico , Diuréticos/uso terapéutico , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Inhibidores de los Simportadores del Cloruro de Sodio/uso terapéutico , Presión Sanguínea/fisiología , Clortalidona/farmacocinética , Ensayos Clínicos como Asunto , Diuréticos/farmacocinética , Evaluación de Medicamentos , Humanos , Hidroclorotiazida/farmacocinética , Hipertensión/sangre , Hipertensión/fisiopatología , Inhibidores de los Simportadores del Cloruro de Sodio/farmacocinética , Resultado del TratamientoRESUMEN
Thiazide diuretics are one of the preferred pharmacologic treatments for hypertension. Hydrochlorothiazide and chlorthalidone have been the 2 most commonly used diuretics in major clinical trials. Treatment guidelines and compendia often consider these 2 drugs interchangeable agents within the class of thiazide or thiazide-like diuretics. Many sources list them as equipotent. Despite these beliefs, there is some suggestion that cardiovascular outcomes are not necessarily the same with these 2 drugs. We conducted a literature search from 1960 to 2003 to identify studies that evaluated the pharmacokinetic and blood pressure-lowering effects of these 2 agents. There are significant pharmacokinetic and pharmacodynamic differences between these diuretics. Chlorthalidone is approximately 1.5 to 2.0 times as potent as hydrochlorothiazide, and the former has a much longer duration of action. Whether these pharmacokinetic and pharmacodynamic features cause differences in outcomes is not known.
Asunto(s)
Antihipertensivos/administración & dosificación , Clortalidona/administración & dosificación , Hidroclorotiazida/administración & dosificación , Inhibidores de los Simportadores del Cloruro de Sodio/administración & dosificación , Antihipertensivos/farmacocinética , Antihipertensivos/uso terapéutico , Clortalidona/farmacocinética , Clortalidona/uso terapéutico , Ensayos Clínicos como Asunto , Diuréticos , Relación Dosis-Respuesta a Droga , Humanos , Hidroclorotiazida/farmacocinética , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Inhibidores de los Simportadores del Cloruro de Sodio/farmacocinética , Inhibidores de los Simportadores del Cloruro de Sodio/uso terapéuticoRESUMEN
Atenolol (CAS 29122-68-7) and chlortalidone (CAS 77-36-1) are marketed associated in a 4:1 strength ratio (100/25 and 50/12.5 mg) for the treatment of hypertension. According to EU guidelines, the bioequivalence of one dosage strength can also cover additional strengths when the pharmacokinetics of a given drug is linearly related with the dose. The kinetics of atenolol is linearly correlated with the dose and chlortalidone has linear kinetics with doses < or = 100 mg. Thus this trial carried out on the 100/25 mg strength also covers the 50/12.5 mg strength. The trial was carried out on 18 healthy volunteers (9 males and 9 females) according to a single dose, two-period, two-treatment, two-sequence study design with washout. Timed atenolol plasma concentrations and chlortalidone blood concentrations were used to assess primary pharmacokinetic parameters Cmax, tmax and AUC extrapolated to infinity by a non-compartmental model. The bioavailability of the two formulations was compared through the 90% confidence intervals (C.I.) of Cmax and AUC in accordance with operating guidelines. C.I. of chlortalidone were fully comprised in the 0.80-1.25 range. In the case of atenolol, which displayed a higher data dispersion, C.I. were comprised in the enlarged 0.70-1.43 range. Time to peak, tmax, did not show any statistically significant difference between the test and reference product with respect to both analytes. Pharmacodynamic measurements of the decrease in systolic blood pressure led to fully overlapping results with test and reference. The authors conclude that the test formulation should be considered bioequivalent with the reference with chlortalidone and in the borderline of bioequivalence with atenolol. As no safety problems were involved and pharmacodynamics led to overlapping results as between test and reference, the bioequivalence conclusion could be extended also to atenolol.
Asunto(s)
Antagonistas Adrenérgicos beta/farmacocinética , Antihipertensivos/farmacocinética , Atenolol/farmacocinética , Benzotiadiazinas , Clortalidona/farmacocinética , Inhibidores de los Simportadores del Cloruro de Sodio/farmacocinética , Antagonistas Adrenérgicos beta/administración & dosificación , Adulto , Antihipertensivos/administración & dosificación , Área Bajo la Curva , Atenolol/administración & dosificación , Disponibilidad Biológica , Clortalidona/administración & dosificación , Diuréticos , Combinación de Medicamentos , Femenino , Semivida , Humanos , Masculino , Inhibidores de los Simportadores del Cloruro de Sodio/administración & dosificación , Equivalencia TerapéuticaRESUMEN
An HPLC method developed to detect in a single run both atenolol and chlorthalidone, extracted from plasma, using two detectors (UV for chlorthalidone and fluorometric for atenolol) connected in series, is described. The drugs were separated on an ODS column at room temperature using a 0.05 M sodium dodecyl sulphate in phosphate buffer (pH 5.8)-n-propanol (95:5, v/v) solution, delivered at a flow-rate of 1.3 ml/min. Having ascertained the sensitivity (10 ng/ml of both drugs) and the intra-day reproducibility (pre-study validation), the reliability of the method was verified by inter-day assays (within-study validation) carried out during the analysis of plasma samples collected from healthy volunteers after single-dose treatment with atenolol+chlorthalidone tablets (pharmaceutical preparations containing 100+25 mg and 50+12.5 mg of the two drugs, respectively).
Asunto(s)
Antihipertensivos/sangre , Atenolol/sangre , Clortalidona/sangre , Cromatografía Líquida de Alta Presión/métodos , Antihipertensivos/farmacocinética , Atenolol/farmacocinética , Clortalidona/farmacocinética , Humanos , Valores de Referencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de FluorescenciaRESUMEN
PURPOSE: The purpose of this study were to evaluate the use of individual compartmental and population compartmental methods for bioequivalence determination, and to determine their utility as adjuncts to the current methods used for bioequivalence assessment. METHODS: Data from three bioequivalence studies of chlorthalidone were analyzed with PCNONLIN using individual compartmental modeling and NONMEM for population analyses. These results were compared with results obtained from the traditional noncompartmental or SHAM (slopes, heights, areas, and moments) approach for bioequivalence assessment and the 90% confidence interval procedure. RESULTS: Individual compartmental modeling and population compartmental modeling techniques performed well on this routine set of bioequivalence data which displayed simple pharmacokinetic properties. A direct assessment of the analysis methods was made by comparing the final estimates and 90% confidence intervals for the test to reference ratios (T/R) of AUC and CMAX. The final estimates and 90% confidence intervals for AUC T/R and CMAX T/R were similar and suggest consistency of results, independent of the method used. CONCLUSIONS: These results demonstrate the utility of modeling techniques as adjuncts to the traditional noncompartmental approach for bioequivalence determination.